ATLASATLAS fair value
ATLAS has no fair value for this stock today.
ENDRA Life Sciences (NDRA)
ENDRA Life Sciences stock price today, ATLAS forecast and fair value
Healthcare · Diagnostics & Research · NASDAQ
$4.77▼ -1.04%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on ENDRA Life Sciences in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On ENDRA Life Sciences
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives ENDRA Life Sciences a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $4.02 and $5.39; in 9 out of 10, between $3.10 and $6.99. Estimated annual volatility is 80%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $9.1M
- 52-week high
- $6.95
- 52-week low
- $2.96
- Revenue (12 months)
- $0.0M
- Return on equity
- -152.0%
- Free cash flow (12 months)
- $-6.7M
- Beta
- -0.04
What this means
ATLAS does not publish a fair value for NDRA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks NDRA has traded between $2.96 and $6.95. Today it is 31.4% below that high and 61% above its low.
Its beta is -0.04: it tends to move less than the market.
About the company
ENDRA Life Sciences Inc. is a medical technology company focused on enhancing clinical diagnostic ultrasound through its Thermo Acoustic Enhanced Ultrasound (TAEUS) platform.
Want to see everything about ENDRA Life Sciences?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does ENDRA Life Sciences do?
ENDRA Life Sciences Inc. is a medical technology company focused on enhancing clinical diagnostic ultrasound through its Thermo Acoustic Enhanced Ultrasound (TAEUS) platform.
What is the chance NDRA goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, NDRA ends the month between $4.02 and $5.39.
How big is ENDRA Life Sciences and what is its P/E ratio?
ENDRA Life Sciences's market capitalization is $9.1M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is NDRA?
ATLAS estimates annual volatility at 80%. In a typical month, half of the outcomes end between $4.02 and $5.39.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer